

Abstract

A new administration regimen giving an extended plasma concentration profile of a H^+ , K^+ -
5 ATPase inhibitor. The extended plasma profile is received by two or more consecutive
administrations of a unit dose of a H^+ , K^+ - ATPase with 0.5 - 4 hours interval or by a
pharmaceutical composition with extended release, which may be administered once daily.